## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($313.16)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. HSBC turns more bullish on Amgen (AMGN) into 2026**
- Source: MSN | 20251217T190753 | Bullish | Relevance: 100%
- HSBC has reiterated its "Buy" rating for Amgen (AMGN) and raised its price target to $325, indicating increased confidence in the biotechnology company's future performance into 2026. The firm's bullish outlook suggests expectations of continued growth and positive developments for Amgen.

**2. Migraine and arthritis drugs drop to $299 a month under new Amgen plan**
- Source: Stock Titan | 20251219T192452 | Somewhat-Bullish | Relevance: 100%
- Amgen (NASDAQ:AMGN) has announced a new plan to lower drug costs for American patients, introducing discounted monthly prices of $299 for Aimovig and Amjevita, and an earlier price of $239 for Repatha through its AmgenNow™ program. The company is also reaffirming its commitment to U.S. innovation and manufacturing with an additional $2.5 billion in investments for 2025, alongside receiving industry-specific tariff relief for three years. This initiative aims to make medicines more accessible while investing in domestic growth.

**3. Talbot Financial LLC Purchases 5,839 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251219T115956 | Bullish | Relevance: 100%
- Talbot Financial LLC increased its stake in Amgen Inc. by 11.1% in Q3, purchasing 5,839 additional shares to hold a total of 58,661 shares valued at approximately $16.55 million. This increase follows Amgen's strong Q3 earnings beat, with $5.64 EPS and $9.56 billion in revenue, and an announced quarterly dividend increase to $2.52 per share. Several other institutional investors also adjusted their holdings in Amgen during recent quarters.

**4. Czech National Bank Has $38.59 Million Stock Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251218T095953 | Bullish | Relevance: 100%
- The Czech National Bank increased its stake in Amgen Inc. (NASDAQ:AMGN) by 4.0% in Q3, now holding 136,733 shares valued at approximately $38.59 million. Amgen reported strong Q3 earnings, beating analyst expectations, and raised its quarterly dividend to $2.52 per share. Analyst ratings for Amgen are generally positive, with an average target price of $332.85, while company insiders sold shares worth about $3.67 million in the last quarter.

**5. Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues**
- Source: Citeline News & Insights | 20251218T090745 | Somewhat-Bullish | Relevance: 100%
- Inductive Bio and Amgen are collaborating with ARPA-H on an initiative to replace traditional animal toxicology testing with advanced AI and human tissue models. This partnership aims to revolutionize drug discovery and development by utilizing cutting-edge technology to improve the accuracy and ethical standards of toxicity assessments. The move signifies a growing trend towards incorporating artificial intelligence and human-centric approaches in biomedical research.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Forward P/E 14.9x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $176.3B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 14.9 |
| Current P/E | 15.4 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-1.43), momentum weakening. RSI neutral at 52. Elevated volume (2.0x 20MA), institutional activity likely. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.28% (CS: 36) | Neutral |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | -1.43 | Bearish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.101x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $327.38
- **Stop Loss:** $313.16 (4.3% risk)
- **Target:** $355.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $27,499.92
- **Portfolio %:** 27.50%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*